Ohbayashi Fumi, Balamotis Michael A, Kishimoto Atsuhiro, Aizawa Emi, Diaz Arturo, Hasty Paul, Graham Frank L, Caskey C Thomas, Mitani Kohnosuke
Gene Therapy Division, Research Center for Genomic Medicine, Saitama Medical School, 1397-1 Yamane, Hidaka, Saitama 350-1241, Japan.
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13628-33. doi: 10.1073/pnas.0506598102. Epub 2005 Sep 7.
For gene therapy of inherited diseases, targeted integration/gene repair through homologous recombination (HR) between exogenous and chromosomal DNA would be an ideal strategy to avoid potentially serious problems of random integration such as cellular transformation and gene silencing. Efficient sequence-specific modification of chromosomes by HR would also advance both biological studies and therapeutic applications of a variety of stem cells. Toward these goals, we developed an improved strategy of adenoviral vector (AdV)-mediated HR and examined its ability to correct an insertional mutation in the hypoxanthine phosphoribosyl transferase (Hprt) locus in male mouse ES cells. The efficiency of HR was compared between four types of AdVs that contained various lengths of homologies at the Hprt locus and with various multiplicities of infections. The frequency of HR with helper-dependent AdVs (HD AdVs) with an 18.6-kb homology reached 0.2% per transduced cell at a multiplicity of infection of 10 genomes per cell. Detection of random integration at DNA levels by PCR revealed extremely high efficiency of 5% per cell. We also isolated and characterized chromosomal sites where HD AdVs integrated in a random manner. In contrast to retroviral, lentiviral, and adeno-associated viral vectors, which tend to integrate into genes, the integration sites of AdV was distributed randomly inside and outside genes. These findings suggest that HR mediated by HD AdVs is efficient and relatively safe and might be a new viable option for ex vivo gene therapy as well as a tool for chromosomal manipulation of a variety of stem cells.
对于遗传性疾病的基因治疗而言,通过外源DNA与染色体DNA之间的同源重组(HR)进行靶向整合/基因修复,将是一种理想的策略,可避免随机整合可能带来的诸如细胞转化和基因沉默等严重问题。通过HR对染色体进行高效的序列特异性修饰,也将推动各种干细胞的生物学研究和治疗应用。为实现这些目标,我们开发了一种改进的腺病毒载体(AdV)介导的HR策略,并检测了其纠正雄性小鼠胚胎干细胞次黄嘌呤磷酸核糖基转移酶(Hprt)基因座插入突变的能力。比较了四种在Hprt基因座含有不同长度同源性且感染复数不同的AdV的HR效率。同源性为18.6 kb的辅助依赖型AdV(HD AdV)在每个细胞10个基因组的感染复数下,每个转导细胞的HR频率达到0.2%。通过PCR在DNA水平检测随机整合,结果显示每个细胞的效率极高,达到5%。我们还分离并鉴定了HD AdV以随机方式整合的染色体位点。与倾向于整合到基因中的逆转录病毒、慢病毒和腺相关病毒载体不同,AdV的整合位点在基因内外随机分布。这些发现表明,HD AdV介导的HR是高效且相对安全的,可能是一种用于体外基因治疗的新的可行选择,也是一种用于各种干细胞染色体操作的工具。